BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Numan S, Faccin F. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. Adv Ther 2018;35:1295-332. [PMID: 30084060 DOI: 10.1007/s12325-018-0742-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Hellström PM, Gemmen E, Ward HA, Koo H, Faccin F, Xue Z, Malmborg P. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study. Scand J Gastroenterol 2022;57:1435-42. [PMID: 35833832 DOI: 10.1080/00365521.2022.2090275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld K, Schaible J, Mccabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. [DOI: 10.1007/s40257-022-00708-w] [Reference Citation Analysis]
3 Niazi SK. Biosimilars: Harmonizing the Approval Guidelines. Biologics 2022;2:171-95. [DOI: 10.3390/biologics2030014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Benucci M, Damiani A, Russo E, Li Gobbi F, Grossi V, Amedei A, Infantino M, Manfredi M. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. JPM 2022;12:1174. [DOI: 10.3390/jpm12071174] [Reference Citation Analysis]
5 Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Adv Ther 2022. [PMID: 35737227 DOI: 10.1007/s12325-022-02173-7] [Reference Citation Analysis]
6 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
7 Fisher A, Kim JD, Carney G, Dormuth C. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia. BMC Rheumatol 2022;6. [DOI: 10.1186/s41927-021-00235-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022;36:359-71. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs 2021;81:1881-96. [PMID: 34596876 DOI: 10.1007/s40265-021-01601-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
11 Ebbers HC. Biosimilarity and Interchangeability of Biologic Drugs‐General Principles, Biophysical Tests, and Clinical Requirements to Demonstrate Biosimilarity. Biologics, Biosimilars, and Biobetters 2020. [DOI: 10.1002/9781119564690.ch7] [Reference Citation Analysis]
12 Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Adv Ther 2020;37:4491-518. [PMID: 32910420 DOI: 10.1007/s12325-020-01472-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
13 Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther 2020;108:734-55. [PMID: 32236956 DOI: 10.1002/cpt.1836] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
14 Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? Rheumatol Ther. 2020;7:35-64. [PMID: 31950442 DOI: 10.1007/s40744-019-00190-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
15 Felice C, Pugliese D, Armuzzi A. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. Expert Opinion on Biological Therapy 2019;19:967-969. [DOI: 10.1080/14712598.2019.1566455] [Reference Citation Analysis]
16 Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019;149:104473. [PMID: 31585178 DOI: 10.1016/j.phrs.2019.104473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
17 Mkinsi O, Lefkir-tafiani S, Srairi HS, Kochbati S, El Dershaby YM, El Azhari MM, Midjek SA, Ladjouze-rezig A. Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. TORJ 2019;13:72-84. [DOI: 10.2174/1874312901913010072] [Reference Citation Analysis]
18 Dolinar R, Kohn CG, Lavernia F, Nguyen E. The non-medical switching of prescription medications. Postgraduate Medicine 2019;131:335-41. [DOI: 10.1080/00325481.2019.1618195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
19 Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5:e000900. [PMID: 31245050 DOI: 10.1136/rmdopen-2019-000900] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
20 Edwards CJ, Hercogová J, Albrand H, Amiot A. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019;19:1001-14. [PMID: 31056970 DOI: 10.1080/14712598.2019.1610381] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Bakalos G, Zintzaras E. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Clin Ther. 2019;41:155-173.e13. [PMID: 30551802 DOI: 10.1016/j.clinthera.2018.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]